PROSPECTUS SUMMARY
This summary highlights information contained or incorporated by reference in this prospectus supplement. Because it is only a summary, it
does not contain all of the information that may be important to you or that you should consider before making an investment in our common stock. You should carefully read the entire prospectus and the accompanying prospectus, including the
information contained under the caption Risk Factors and elsewhere in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and our most recent Quarterly
Report on Form 10-Q for the fiscal quarter ended September 30, 2019, the information under Risk Factors beginning on page S-7 of this prospectus
supplement and other information that we file from time to time with the SEC as well as the financial statements and related notes and the other information incorporated by reference herein, before making an investment decision. See Where You
Can Find More Information and Incorporation of Certain Documents By Reference in this prospectus supplement. This prospectus supplement may add to, update or change information in the accompanying prospectus. Unless the context
otherwise requires, all references in this prospectus supplement to Inovio, we, us, our, the Company or similar words refer to Inovio Pharmaceuticals, Inc., together with our consolidated
subsidiaries.
Our Company
We are an innovative clinical stage biotechnology company focused on the discovery, development, and commercialization of our synthetic DNA
technology targeted against cancers and infectious diseases. Our DNA-based immunotherapies and vaccines, in combination with our proprietary, efficacy-enabling delivery devices, are intended to generate robust
immune responses, in particular functional CD8+ killer T cells and antibodies, to fight targeted diseases.
Our novel SynCon® immunotherapy design has shown the ability to help break the immune systems tolerance of cancerous cells. Our SynCon® product design
approach is also intended to facilitate cross-strain protection against known and new unmatched strains of pathogens, such as influenza. Our CELLECTRA® delivery system facilitates optimized
cellular uptake of the SynCon® immunotherapies, overcoming a key limitation of other DNA-based immunotherapies. Human data to date have shown a
favorable safety profile of our SynCon® immunotherapies delivered using CELLECTRA® in over 6,000 administrations across almost 2,000
patients.
We or our collaborators are currently conducting or planning clinical studies of our proprietary SynCon® immunotherapies for HPV-caused pre-cancers, including cervical, vulvar, and anal dysplasia; HPV-caused cancers, including head & neck, cervical, anal, penile, vulvar, and vaginal; other HPV-caused disorders, such as recurrent respiratory papillomatosis, or
RRP; glioblastoma multiforme, or GBM; prostate cancer; hepatitis B virus; hepatitis C virus; HIV; Ebola; Middle East Respiratory Syndrome, or MERS; Lassa fever; and Zika virus. We also recently announced our intention to accelerate the clinical
development of our DNA-encoded bi-specific T cell engagers, or dBTE, technology and build on recent advances observed with our
DNA-encoded monoclonal antibody, or dMAb, technology.
Our corporate strategy is to advance,
protect and exploit our differentiated immunotherapy platform. Through the use of our unique capabilities on both design and development, we continue to progress and validate an array of HPV related diseases, as well as cancer and infectious disease
immunotherapy and vaccine products. We aim to advance products through to commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. Our partners and collaborators
include AstraZeneca, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG/Genentech, Inc., ApolloBio Corporation, GeneOne Life Science Inc., The Bill and Melinda Gates Foundation, The Parker Institute for
Cancer Immunotherapy, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, National Institutes of Health, HIV Vaccines Trial Network, National Cancer Institute, Walter Reed Army Institute of Research, Medical
CBRN Defense Consortium, The Wistar Institute and the University of Pennsylvania.